Physician profile
Karen Brown
NPI 1558342956
$17,392.13
in general payments reported to CMS, 2019-2025
39 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 94% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,363 · 2020: $2,805 · 2021: $5,590 · 2022: $1,785 · 2023: $1,267 · 2024: $1,708 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,792 · Education: $56.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,791.66 |
| Education | $56.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,057.24 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $1,845.21 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,305.54 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,274.63 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,219.32 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $885.43 | 2019-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $774.55 | 2019-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $745.32 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $637.07 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $504.52 | 2019-2025 | Ingrezza |
| Corium, LLC | $485.94 | 2021-2025 | Azstarys |
| Alkermes, INC. | $482.24 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $414.56 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $396.57 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $358.73 | 2022-2024 | Qelbree, Qelbree |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $320.33 | 2019-2024 | Jornay Pm |
| Eisai INC. | $303.95 | 2020-2022 | |
| Lundbeck LLC | $296.87 | 2019-2025 | Rexulti |
| Owp Pharmaceuticals, INC. | $228.77 | 2019-2025 | Subvenite |
| Merck Sharp & Dohme LLC | $204.68 | 2020-2023 | Belsomra |
| Noven Therapeutics, LLC | $195.55 | 2020-2025 | Xelstrym, Secuado |
| Indivior INC. | $186.86 | 2019-2024 | Sublocade |
| Axsome Therapeutics, INC. | $135.60 | 2022-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $129.63 | 2021-2025 | Loreev Xr |
| Neos Therapeutics, LP | $129.34 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $119.08 | 2019-2021 | |
| Adlon Therapeutics L.P. | $117.93 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $116.70 | 2019-2022 | |
| Tris Pharma INC | $106.08 | 2019-2020 | |
| Shire North American Group INC | $105.29 | 2019 | |
| Vertical Pharmaceuticals, LLC | $74.96 | 2019-2025 | Relexxii |
| Orexo US, INC. | $50.12 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $40.76 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $37.44 | 2019-2020 | |
| Noven Pharmaceuticals, INC. | $27.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.17 | 2025 | Cobenfy |
| Alfasigma USA, INC. | $17.50 | 2020 | |
| Livanova USA, INC. | $16.68 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $16.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.